Silodosin

In the US, Silodosin (silodosin systemic) is a member of the drug class antiadrenergic agents, peripherally acting and is used to treat Benign Prostatic Hyperplasia.

US matches:

• Silodosin

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

G04CA04

CAS registry number (Chemical Abstracts Service)

0160970-54-7

Chemical Formula

C25-H32-F3-N3-O4

Molecular Weight

495

Therapeutic Categories

Treatment of symptoms of benign prostatic hyperplasia

α1a-adrenoceptor antagonist

Chemical Names

(-)-1-(3-hydroxypropyl)-5-[(2R)-2-[[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl]amino]propyl]-2,3-dihydro-1H-indole-7-carboxamide (WHO)

1-(3-Hydroxypropyl)-5-[(2R)-2-[2-[2-(2,2,2-trifluorethoxy)phenoxy]ethylamino]propyl]-2,3-dihydro-1H-indol-7-carbamid (IUPAC)

2,3-Dihydro-1-(3-hydroxypropyl)-5-[(2R)-2-[[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl]amino]propyl]-1H-indole-7-carboxamide

Foreign Names

• Silodosinum (Latin)
• Silodosin (German)
• Silodosine (French)
• Silodosina (Spanish)

Generic Names

• Silodosin (OS: JAN)
• KAD-3213 (IS: Kissei)
• KMD-3213 (IS: Kissei)

Brand Names

• Rapaflo
  Watson, United States



• Urief
  Kissei, Japan



• Urorec
  Merckle Recordati, Germany

International Drug Name Search

Glossary

IUPAC	International Union of Pure and Applied Chemistry
IS	Inofficial Synonym
JAN	Japanese Accepted Name
OS	Official Synonym
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)
WHO	World Health Organization

Click for further information on drug naming conventions and International Nonproprietary Names.